Solving costly tablet manufacturing issues
![](/46/pdcnewsitem/07/41/27/drugs-healthcare-medical-208541.jpg)
I Holland to share their 70 years' experience in an ‘ultimate’ tooling seminar.
With more than 70 years of experience in the tablet tooling industry, I Holland has a wealth of knowledge on productive manufacturing techniques. In order to share their expertise, the company will be hosting the ‘Ultimate Guide to Compression Tooling’ seminar on 19-20 September at its head office in Nottingham, UK.
I Holland’s leading team of experts have created a seminar which looks at all the major factors in compression tooling, including common problems encountered during tablet production, punch and die design, tooling specification and how by improving maintenance and aftercare procedures downtime can be significantly reduced.
Marianna D’Onghia, I Holland’s host for the event said: “The Ultimate Guide to Compression Tooling seminar really is an all-encompassing view at tablet tooling. It has run on several occasions and has proved to be extremely popular with customers joining us from around the world.
“The team of experts at I Holland have an enormous pool of experience in various areas of tablet tooling, from design to maintenance. Combining this with over 70 years of research and development, I Holland can really help companies with their tablet manufacturing processes.
“In light of the increased pressure on manufacturers to get a quality product out quickly and cost-effectively, we are called on more frequently to solve tablet manufacturing problems. The seminar has been designed specifically for production managers, press operators and those directly involved in tooling maintenance and will include sharing information on industry trends and tooling expertise to help avoid costly production issues in both money and time. All of the information shared will help in effectively producing quality tablets and relieving customer pressure.
“The seminar will include focusing on some of the most common problems encountered during production including sticking, picking, corrosion, abrasion and tooling damage. There will also be a tour of I Holland’s facilities, where delegates can see punch manufacture from design through to despatch of the final product. It will also give us the opportunity to discuss individual cases with those that attend both in group and individual scenarios. We can then gain informative feedback on how I Holland can further assist in problem-solving.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance